Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV)

Key Points

• Options activity surged: Traders purchased 7,491 ROIV call options, 421% above the average volume of 1,438 contracts.
• Shares jumped 19.4% to $41.69 on heavy trading volume, approaching the 52-week high of $42.09. The stock’s market capitalization reached approximately $30.1 billion.
• Analyst sentiment remains favorable: Roivant has an overall “Moderate Buy” rating, with an average price target of $37.14, while Jefferies raised its target to $52. Insiders, however, sold more than 3 million shares worth about $107.3 million during the last quarter.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) was the target of unusually large options trading on Tuesday. Traders acquired 7,491 call options on the company. This is an increase of 421% compared to the average volume of 1,438 call options.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Friday, August 28th. The stock was sold at an average price of $35.77, for a total transaction of $7,154,000.00. Following the completion of the sale, the chief executive officer owned 1,599,154 shares of the company's stock, valued at $57,201,738.58. This trade represents a 11.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Gold sold 12,380 shares of Roivant Sciences stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the transaction, the director directly owned 13,689,166 shares of the company's stock, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055,913 shares of company stock worth $107,261,258 in the last quarter. Insiders own 8.80% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ROIV. SBI Securities Co. Ltd. increased its position in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its position in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after buying an additional 583 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC grew its stake in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of Roivant Sciences by 7,614.3% during the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock worth $59,000 after buying an additional 2,665 shares in the last quarter. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Trading Up 19.4%

NASDAQ ROIV traded up $6.76 on Tuesday, hitting $41.69. 11,196,290 shares of the company's stock were exchanged, compared to its average volume of 6,163,936. The stock has a 50-day moving average of $35.30 and a 200-day moving average of $31.26. The stock has a market cap of $30.11 billion, a price-to-earnings ratio of -79.15 and a beta of 1.12. Roivant Sciences has a 52 week low of $12.90 and a 52 week high of $42.09.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to analysts' expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, analysts predict that Roivant Sciences will post -2 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on ROIV. Piper Sandler reiterated an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Jefferies Financial Group increased their target price on Roivant Sciences from $42.00 to $52.00 and gave the stock a "buy" rating in a report on Tuesday. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a research report on Tuesday, August 25th. Guggenheim boosted their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Finally, Citigroup upped their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of "Moderate Buy" and an average price target of $37.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.